Catabasis Pharmaceuticals (CATB) Rating Reiterated by Wedbush
Catabasis Pharmaceuticals (NASDAQ:CATB)‘s stock had its “outperform” rating reiterated by stock analysts at Wedbush in a report released on Friday. They presently have a $4.00 target price on the biotechnology company’s stock. Wedbush’s price objective suggests a potential upside of 142.42% from the company’s previous close.
A number of other research firms also recently issued reports on CATB. CIBC reissued an “outperform” rating and issued a $7.00 target price (up from $4.00) on shares of Catabasis Pharmaceuticals in a research report on Thursday, October 5th. Zacks Investment Research raised Catabasis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a research report on Thursday, November 16th. Oppenheimer raised their target price on Catabasis Pharmaceuticals from $4.00 to $7.00 and gave the stock an “outperform” rating in a research report on Thursday, October 5th. Citigroup reissued a “hold” rating and issued a $1.50 target price on shares of Catabasis Pharmaceuticals in a research report on Friday, September 29th. Finally, Cowen reissued a “market perform” rating and issued a $2.00 target price on shares of Catabasis Pharmaceuticals in a research report on Friday, October 6th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $4.82.
Catabasis Pharmaceuticals (NASDAQ CATB) traded down $0.07 during trading hours on Friday, reaching $1.65. The company’s stock had a trading volume of 227,766 shares, compared to its average volume of 997,131. Catabasis Pharmaceuticals has a twelve month low of $1.08 and a twelve month high of $5.51.
Several institutional investors have recently bought and sold shares of CATB. Renaissance Technologies LLC bought a new position in shares of Catabasis Pharmaceuticals in the first quarter worth $106,000. Oppenheimer & Co. Inc. boosted its holdings in shares of Catabasis Pharmaceuticals by 33.3% in the second quarter. Oppenheimer & Co. Inc. now owns 120,000 shares of the biotechnology company’s stock worth $169,000 after acquiring an additional 30,000 shares during the period. Virtu KCG Holdings LLC bought a new position in shares of Catabasis Pharmaceuticals in the second quarter worth $271,000. Finally, Wedbush Securities Inc. boosted its holdings in shares of Catabasis Pharmaceuticals by 2,368.6% in the third quarter. Wedbush Securities Inc. now owns 251,802 shares of the biotechnology company’s stock worth $534,000 after acquiring an additional 241,602 shares during the period. 33.14% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “Catabasis Pharmaceuticals (CATB) Rating Reiterated by Wedbush” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/12/15/catabasis-pharmaceuticals-catb-rating-reiterated-by-wedbush.html.
About Catabasis Pharmaceuticals
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.